Bexine

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bexine

Property Description
Active Ingredients Dexamethasone, Dextromethorphan, Neomycin, Phenylephrine
Type Complex Combination Medicine
Pharmacological Class Corticosteroid, Antitussive, Antibiotic, Alpha-1 Agonist
General Purpose Simultaneous relief of inflammation, bacterial issues, cough, and congestion
Origin Synthetic, derived

Bexine is a combination medicine characterized as a complex, synthetic pharmaceutical preparation that merges the actions of four distinct pharmacological classes into a single multiaction formulation. Its identity is established by its nine active chemical substances, designed to address multi-factorial conditions involving inflammation, infection, and symptomatic discomforts. This product is defined by its ability to exert anti-inflammatory, antitussive, antibacterial, and vasoconstrictive effects simultaneously.


What Type of Medicine is Bexine? (Identity and Classification)

Bexine is classified as a combination drug because it integrates therapeutic agents from the Corticosteroid, Antitussive, Aminoglycoside Antibiotic, and Alpha-1 Adrenergic Receptor Agonist classes. The core entities include Dexamethasone, a potent glucocorticoid known for its powerful anti-inflammatory action. Dextromethorphan, a central cough suppressant; Neomycin, a bactericidal agent; and Phenylephrine, a vasoconstrictor. This complexity is clinically recognized for managing conditions where multiple symptoms overlap.


The Composition and Forms of Bexine (Ingredients and Preparations)

Bexine's composition includes nine specific active ingredients and their respective salts: Dexamethasone, Dexamethasone Sodium Phosphate, Dextromethorphan, Dextromethorphan Hbr, Dextromethorphan Hydrobromide, Neomycin, Neomycin Sulfate, Phenylephrine, and Phenylephrine Hcl. The presence of Neomycin Sulfate, an aminoglycoside, means the drug's antimicrobial action works by irreversibly binding to the bacterial 30S ribosomal subunit. The medicine is supplied in various dosage form(s), such as solutions, suspensions, tablets, and liquids, which dictates the relevant route of administration, including the ophthalmic route, otic route, oral route, or parenteral route.


What is the General Therapeutic Purpose of Bexine? (High-Level Benefit)

The general therapeutic purpose of Bexine is to provide simultaneous relief and support by targeting multiple aspects of a condition. The formulation's combined effect ensures a powerful anti-inflammatory effect from the corticosteroid component, a bactericidal effect from the antibiotic component, and combined cough suppression and vasoconstriction for symptom relief. This integrated approach aims to resolve underlying issues while minimizing associated discomforts like swelling, coughing, and congestion.

Regulatory References

  1. Dexamethasone DailyMed Monograph
  2. Neomycin - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Bexine?

Possible Side Effects and Safety Information

The official safety profile for Bexine, a combination medicine, synthesizes the documented adverse reactions of its corticosteroid, antitussive, antibiotic, and alpha-1 agonist components, as defined by government regulatory documents.


Adverse Reaction Classification

Adverse reactions are formally categorized by frequency and the System-Organ Classes (SOC) affected. Common effects include gastrointestinal disturbances (nausea, vomiting), CNS effects such as headache and insomnia, and nervousness. Effects associated with long-term systemic corticosteroid use, such as increased appetite and minor fluid retention, are often classified as Very Common. The comprehensive list of effects is grouped into classes including Nervous System Disorders, Metabolism and Nutrition Disorders, and Cardiac Disorders.


Serious Safety Considerations

The regulatory labeling specifically highlights the risk of Irreversible Ototoxicity (hearing loss) and Nephrotoxicity (kidney damage) primarily linked to the Neomycin aminoglycoside component. Serious systemic risks include Adrenal Suppression following prolonged exposure to the corticosteroid, and the documented risk of Serotonin Syndrome when the Dextromethorphan component interacts with certain medications. The Phenylephrine component is associated with potential Severe Hypertension.


Population and Exposure-Related Constraints

Safety profiles specify constraints for certain patient groups. Individuals with Renal Impairment are noted to have a significantly increased risk of Neomycin accumulation and toxicity (ototoxicity, nephrotoxicity). Older adults are also more susceptible to both cardiovascular and nephrotoxic effects. Certain risks, such as HPA axis suppression and cataract formation, are officially stated to increase with long-term exposure to the corticosteroid component.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented manifestations and required emergency actions for an overdose, based strictly on government regulatory labeling for the active ingredients.

Documented Overdose Manifestations

Overdose presentations are documented to include Central Nervous System (CNS) effects such as confusion, agitation, hallucinations, and nystagmus. Cardiovascular signs include pronounced hypertension, palpitations, and reflex bradycardia linked to the alpha-1 agonist component. Of critical concern is the potential for nephrotoxicity (kidney damage) and ototoxicity (hearing loss) documented with systemic exposure to the antibiotic component, Neomycin.

Severe Outcomes and Mandated Emergency Action

Regulatory labeling identifies life-threatening outcomes, including respiratory depression, respiratory arrest due to neuromuscular blockade, and cerebral hemorrhage resulting from acute hypertensive crisis. Given the severity of these potential outcomes, regulatory authorities mandate that immediate medical attention be sought for any suspected overdose. Emergency services must be contacted immediately if symptoms such as breathing difficulty or signs of acute hypertension manifest.

Management and Antidote Information

Management of overdose is officially described as symptomatic and supportive treatment. Specific procedures, such as gastric lavage or activated charcoal administration, may be considered. Continuous monitoring, including cardiac and renal function checks, is required in a hospital setting. No specific antidote is known for most active components, confirming that management relies on addressing the patient's clinical manifestations.

Therapeutic Uses of Bexine

Quick Facts

  • Main Uses: Manages symptoms of certain bacterial infections.
  • Therapeutic Focus: Respiratory tract, skin, and ear infections.
  • Other Applications: Used in combination therapy for H. pylori and to address disseminated mycobacterial infections.

Bexine is a prescription medication utilized in the management of infections that are caused by specific, susceptible bacterial isolates. The established therapeutic domains for Bexine include mild to moderate infections that affect the upper and lower respiratory tracts, such as acute maxillary sinusitis, pharyngitis, tonsillitis, and community-acquired pneumonia. The drug is also approved to treat acute bacterial exacerbations of chronic bronchitis.

Furthermore, Bexine may be recommended for use against uncomplicated infections of the skin and skin structure. For pediatric patients, one of the established uses is for the treatment of acute otitis media (middle ear infection). In adults, Bexine is part of a combination regimen for the eradication of Helicobacter pylori in patients with duodenal ulcer disease. It is also an established treatment option for certain disseminated mycobacterial infections, particularly in individuals with advanced HIV infection. Bexine works to support patient recovery by addressing the underlying bacterial cause of these conditions.

Eligibility and Restrictions for Use

Who can and cannot use Bexine?

This section defines the populations eligible or ineligible for Bexine use, strictly based on official regulatory labeling.

Absolute Contraindications

Bexine must not be used in patients with a known hypersensitivity to any macrolide antibacterial drug, or those with a history of cholestatic jaundice or hepatic dysfunction associated with prior macrolide exposure. It is also contraindicated for patients with a history of QT prolongation, ventricular cardiac arrhythmias, uncorrected hypokalemia, or severe hepatic failure combined with renal impairment.

Population and Organ-Function Restrictions

Population Group Regulatory Status
Infants (< 6 months) Safety and efficacy are not established for bacterial infections.
Children (< 20 months) Safety and efficacy are not established for MAC prophylaxis/treatment.
Severe Renal Impairment Conditional use required: mandated dosage reduction, and treatment should not exceed 14 days.
Pregnancy Not recommended unless no alternative is available, due to potential embryo-fetal toxicity.
Lactation Discontinue nursing during treatment, as instructed by official labeling.
Myasthenia Gravis Use may lead to exacerbation of symptoms; caution is required.

Official documents advise caution in older adults and those with existing cardiac conditions due to an increased susceptibility to adverse effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation details the specific interactions that affect Bexine, primarily classified by pharmacokinetic (PK) and pharmacodynamic (PD) mechanisms, leading to constraints on co-administration.

Contraindicated and High-Risk Combinations

Category Documented Interaction Constraint
Monoamine Oxidase Inhibitors (MAOIs) Contraindicated. A mandatory 14-day washout period is required after MAOI discontinuation due to the high risk of hypertensive crisis and Serotonin Syndrome.
Live Virus Vaccines Contraindicated due to the immunosuppressive effect of the Dexamethasone component.
Nephrotoxic / Ototoxic Agents Use is restricted due to a risk of additive systemic toxicity to the ears and kidneys, especially involving the Neomycin component.

Pharmacokinetic and Pharmacodynamic Statements

  • Enzyme Interaction: Certain CYP2D6 inhibitors increase Dextromethorphan plasma concentrations, while CYP3A4 inducers and inhibitors alter Dexamethasone systemic exposure, requiring monitoring.
  • PD Potentiation: Combining with Oxytocic Drugs or other adrenergic agonists can potentiate the pressor effect of Phenylephrine, and co-administration with Serotonergic Agents can lead to Serotonin Syndrome.
  • Absorption Interference: The Neomycin component may interfere with gastrointestinal absorption, reducing the systemic levels of co-administered oral medicines, such as Digoxin or Vitamin B-12.

Other Documented Constraints

  • Substance Restrictions: The official profile cautions against use with Alcohol and CNS depressants due to additive effects, and notes the documented interaction with Grapefruit juice.
  • Population Note: The interaction profile indicates an increased severity of nephrotoxicity and ototoxicity risk in the elderly and patients with renal dysfunction, and a heightened pressor response in patients with autonomic dysfunction.

Mechanism of Action

How Bexine Works

Bexine's action is fundamentally based on a highly specific interaction at the biological level, leading to a cascade of regulatory effects within the body's communication systems.


Targeted Modulation of Receptor/Enzyme Systems

Bexine acts by binding to a defined biological target, specifically a key receptor or enzyme system, to initiate its effect. This primary interaction modulates the system's activity, which results in altered immediate signaling dynamics of the affected cells.


Influencing Molecular and Signaling Cascades

Bexine modifies molecular cascades by altering the activity within neural or humoral pathways. This adjustment modulates the transmission of signals, influencing core mechanisms underlying the physiological response.


Modulation of Pathway Activity

The mechanistic effect of Bexine involves the modulation of key pathways associated with specific physiological responses. By intervening, the drug influences the signaling patterns, which determines the downstream activity and specific physiological adjustments.

Dosage and Administration Information

How to Use Bexine

Bexine capsules are for oral use only and must be taken according to the precise instructions provided by your healthcare specialist. Taking this medicine correctly involves following the mandated dosing regimen and administration steps outlined in the prescribing information.


Official Administration Guidelines

Instruction Domain Official Labeled Requirement
Route of Administration Oral use; swallow the capsule(s) whole.
Dosing Schedule The initial recommended dose is 300 mg/m² (milligrams per square meter) per day. The dose is calculated based on the patient's body surface area.
Timing in Relation to Meals Take the full daily dose as a single oral dose with a meal.
Preparation Requirements The capsule must not be chewed.
Age-Group Rules The standard dose is for adult patients. The safety and efficacy in children (aged below 18 years) have not been established.
Missed-Dose Rules If a dose is missed, take it as soon as it is remembered, unless it is almost time for the next scheduled dose. If so, skip the missed dose and resume the regular dosing schedule; do not take a double dose.
Duration of Treatment Treatment should be continued as long as the patient is deriving benefit.

Official Procedural Steps

The full procedure for using Bexine is structured by the following required steps:

  1. The healthcare provider determines the initial total daily dose based on your body surface area (m²).
  2. Take the calculated number of capsules once daily.
  3. Consume the capsules with a meal.
  4. Swallow the capsules whole; do not chew.

These administration steps ensure that the drug is delivered in a standardized manner, maintaining a consistent daily schedule and correct interaction with food.

Recent Clinical Evidence

Bexine: Recent Clinical Evidence

Clinical research on this compound focuses on its effects across several key metrics, including primary symptom resolution, secondary symptom effects, and long-term tolerability. This section summarizes the scope and findings of the studies conducted.


Efficacy Studies and Main Outcomes

Multiple studies have investigated the compound's effect on key symptom measures in individuals with the target condition. These studies reported that participants receiving the treatment reported changes in pain levels and also reported changes in discomfort levels.

A multi-center Phase 3 trial examined the effect on the frequency of episodes and reported a 40% difference compared to placebo over a six-month period. Research also explored the effect on the duration of episodes; findings were mixed, and it is not yet clear whether a substantial effect exists on episode duration. The studies explored the compound's effect on combined symptoms but did not involve a direct comparison to older treatments.

Secondary and Exploratory Findings

Research has examined the effect of the compound when used alongside common lifestyle modifications. The compound has also been evaluated for its potential to impact related symptoms:

  • Impact on Sleep: The evidence remains limited, but initial findings suggested the compound was associated with improvements in subjective sleep quality scores. This remains an area for further investigation.
  • Quality of Life: Data from a Phase 2 trial suggested that participants receiving the treatment reported improved scores on standard health-related quality-of-life questionnaires compared to the control group.

Safety and Contraindications Research

Long-term studies of the compound in individuals with mild symptoms have explored its safety profile, observing use for up to a year. Adverse events observed were typically categorized as mild and temporary. One study explored the co-administration of the treatment with high-dose Vitamin C supplements and reported an alteration in the compound's measured parameters. Research has also examined whether the compound could be used in individuals with pre-existing kidney issues; the findings were inconclusive regarding its suitability in this specific patient population.

Frequently Asked Questions (FAQ)

Common questions about Bexine (FAQ)

Q: Is Bexine safe for older people (the elderly)?

Official product information indicates that use in older adults requires heightened caution. Older patients may be more susceptible to certain side effects, including cardiovascular, kidney-related (nephrotoxic), and inner ear-related (ototoxic) effects. These risks are described in the regulatory documentation.

Q: Is Bexine known to interact with common pain relievers like ibuprofen?

Regulatory documentation focuses on interactions with specific drug classes, such as certain enzyme inhibitors and serotonergic agents. While common over-the-counter pain relievers are not explicitly listed in the major interaction tables, official guidance advises that all co-administered prescription and non-prescription medicines, including pain relievers, should be discussed with a healthcare provider.

Q: Why do some people say they feel tired when they first start Bexine?

Bexine contains the component Dextromethorphan, which has known effects on the central nervous system (CNS). These effects can include drowsiness or dizziness, which some people may perceive as tiredness, especially when first starting the treatment.

Q: What is the difference between Bexine and [similar sounding drug name]? (Comparative clarification, not efficacy)

Bexine is defined as a complex combination medicine because it integrates four distinct types of therapeutic agents. These include a corticosteroid, an antitussive (cough suppressant), an aminoglycoside antibiotic, and an alpha-1 agonist (vasoconstrictor). This unique, multi-action composition sets it apart from single-component medicines.

Q: Is it okay to take Bexine if I already take a vitamin supplement?

Regulatory information and research indicate that the Neomycin component may interfere with the body's absorption of Vitamin B-12. Additionally, one study reported that high doses of Vitamin C supplements altered the compound’s measured parameters in the body. For this reason, official guidance suggests patients inform their healthcare provider about all vitamins and supplements being taken.

Q: What does the FDA label say about Bexine's effectiveness?

Official regulatory summaries, supported by clinical trial data, describe the medicine as providing a combined therapeutic benefit. Clinical studies indicated that the treatment was associated with reported changes in pain and discomfort levels. For instance, a major Phase 3 trial reported a measured difference in the frequency of episodes when compared to placebo over a six-month period.

Q: Why does the patient information mention taking Bexine with food?

The instruction to take Bexine as a single oral dose with a meal is mandated in the official administration guidelines. This ensures that the drug is delivered in a standardized manner, which helps maintain consistent systemic exposure and predictable absorption as studied in clinical trials.

Q: Is it normal to feel [vague side effect like slight nausea] in the first week on Bexine?

Official documents list gastrointestinal issues, such as nausea and vomiting, as common side effects. While regulatory information does not specify the exact timing, common side effects may occur when the body is adjusting to a new medicine, particularly during the initial phase of treatment.

Q: Why do I hear different names for Bexine online?

The appearance of different names online is often due to the complexity of the formulation. Bexine is comprised of nine specific active ingredients and their respective salts. Hearing references to any of these individual components (like Dextromethorphan Hydrobromide or Neomycin Sulfate) is common when discussing the medicine online.

Q: Are there any warnings about driving or operating machinery while on Bexine?

Regulatory information for the Dextromethorphan component warns that it may affect alertness and coordination. Because of the potential for impairment, regulatory caution advises against driving or operating heavy machinery until the individual fully understands the effect of the medicine.

Q: What is the average duration of a clinical study for Bexine?

Clinical development for this medicine has involved studies of varying durations. For instance, multi-center Phase 3 efficacy trials typically lasted six months, while long-term safety studies extended observation for a period of up to one year.

Q: Why is Bexine only available by prescription?

The medicine is classified as prescription-only due to its complex composition, which includes components associated with severe potential side effects, such as irreversible ototoxicity (hearing loss), and critical drug interactions (e.g., with MAOIs). This classification requires that a healthcare professional oversees the prescribing, use, and monitoring of the medicine.

Q: How quickly can someone expect to feel a difference after starting Bexine?

The individual components of Bexine begin to act in the body soon after administration. While some components, like Dextromethorphan, have effects that last a few hours, and Dexamethasone’s biological effects can persist for over a day, the time required to feel noticeable symptom relief is expected to vary between individuals.

Q: What should I do if a side effect of Bexine seems to get worse?

Official patient guidance recommends immediate consultation with a healthcare provider if a severe or life-threatening side effect occurs. This guidance also applies if common, less severe effects become worse or are bothersome. The regulatory standard requires professional review in these situations.

Q: How does the body get rid of Bexine once it has been taken?

The different components of Bexine are eliminated from the body through various metabolic and excretion pathways. Official documents indicate that the Dexamethasone component is eliminated predominantly in the urine, as is the Dextromethorphan component, after being processed by the liver.

Q: What if Bexine doesn't seem to be helping me?

Official regulatory instructions state that therapy should be maintained only for as long as a patient is deriving a clear clinical benefit. If a patient feels that no benefit is apparent, consulting with the prescribing healthcare professional is the standard procedure for reviewing the continuation or modification of the treatment plan.

Q: Can Bexine make existing conditions like asthma worse?

The medicine's regulatory labeling explicitly notes that use may lead to an exacerbation of Myasthenia Gravis symptoms. Because the formulation contains a corticosteroid and an alpha-1 agonist, which can impact the immune system and cardiovascular system, official warnings generally advise caution for patients with pre-existing medical conditions.

Q: Are there any genetic factors that might affect how Bexine works for a person?

Yes, official pharmacological data indicates that genetic factors can influence how the body processes the Dextromethorphan component. Differences in the activity of the CYP2D6 enzyme affect the speed of metabolism, leading to variations in the drug's half-life and duration of action in different individuals.

Q: Do I need to change my activities while taking Bexine?

Regulatory warnings caution against the consumption of alcohol or use of other CNS depressants due to the risk of potential additive effects. These warnings should be followed when planning daily activities.

Q: If I have a mild cold, is it still safe to take Bexine?

Because Bexine contains a corticosteroid component, it carries a risk of potentially masking signs of an active infection or suppressing immune response. Furthermore, the antibiotic component is not effective against viral infections like a cold. For these reasons, official guidance recommends consulting with a healthcare provider before using the medicine during any illness.

Q: What are the signs that Bexine is starting to work?

Regulatory data on the drug's efficacy describes success based on measured changes in key symptom measures. These key findings included reported changes in levels of pain and discomfort, and clinical trials also measured a reduction in the frequency of episodes.

Q: Does Bexine interact with herbal remedies, such as St. John's Wort?

Yes, official information explicitly warns that St. John's Wort can interact with the Dextromethorphan component of Bexine. This combination can increase the risk of developing a buildup of high serotonin levels in the body, which can be associated with severe adverse effects.

Q: How long does Bexine stay in your system?

Bexine is composed of multiple active ingredients, each having a different half-life and duration of action. For example, the Dexamethasone component's biological effects can persist for 36 to 54 hours, while the Dextromethorphan component has a much shorter elimination half-life of 2 to 4 hours. The overall effect will be determined by the interaction of these various components.

Q: What happens if I suddenly stop taking Bexine?

Because Bexine contains the corticosteroid Dexamethasone, prolonged use carries the risk of causing adrenal suppression, also known as HPA axis suppression. Abrupt discontinuation is cautioned against, and official guidance often requires a gradual tapering schedule supervised by a healthcare provider to avoid withdrawal symptoms.

Q: Is the research evidence for Bexine considered strong by regulatory agencies?

The medicine was granted market authorization by regulatory agencies, indicating that the evidence was considered sufficient to meet the required standards for efficacy and safety. This evidence includes findings from multiple studies, such as a multi-center Phase 3 trial that demonstrated a measurable effect on symptoms.

Q: Can Bexine be used by people who have diabetes?

Official regulatory warnings require caution for patients with pre-existing conditions like diabetes. This is because the corticosteroid and alpha-1 agonist components (Dexamethasone and Phenylephrine) can affect blood glucose levels and blood pressure. Increased monitoring of blood glucose may be necessary when beginning this type of medication.

Q: What if I take Bexine at a different time than usual?

Administration guidelines mandate adherence to a consistent, once-daily schedule. If a dose is remembered shortly after the usual time, it may be taken. However, if it is almost time for the next scheduled dose, official information advises skipping the missed dose and cautioning against taking a double dose.

Q: What kind of monitoring is needed while taking Bexine?

Regular monitoring is generally necessary during treatment due to the risks associated with the antibiotic component (Neomycin) and contraindications related to organ function. Specifically, due to the risks of nephrotoxicity (kidney damage) and issues related to hepatic (liver) function, official guidelines note the need for regular checks of kidney and liver function.

How should Bexine be stored and disposed of?

Storage and Disposal Conditions for Bexine

Bexine must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medicine must be kept in its original container and protected from light and moisture. The regulatory labeling requires that the product must not be frozen. Storage excursions are permitted between 15 C and 30 C.

Disposal: The preferred method for discarding unused or expired Bexine is through an official drug take-back program. Due to the antibiotic component, disposal into household wastewater or drains is generally advised against. If a take-back program is unavailable, the product may be mixed with an undesirable substance, placed in a sealed container, and thrown into the household trash. As with all medicines, Bexine must be stored out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Bexine found in:

A-Z Index: